A Phase 2 Study of SL-325 in Crohn's Disease Patients

Starting soon · Phase 2 · Has a placebo group

Conditions studied: Crohn's Disease

In brief

The primary purpose of this study is to evaluate the efficacy of SL-325 in adult participants with moderate to severely active Crohn's disease. The study consists of a screening period of up to 6 weeks, a 12-week induction period, 38-week maintenance period, 52-week long-term extension period, and a 10-week follow-up period.

Key facts

Study ID

NCT07753850

Run by

Shattuck Labs, Inc.

People needed

232

Starts

2026-10-01

Expected to finish

2030-06-01

Last updated by the study team

2026-08-10

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.